B세포림프종 환자에서 혈청 대식세포집락자극인자 농도 증가와 임상병리학적 특징의 연관성
Association Between Elevated Serum Macrophage Colony-Stimulating Factor Levels and Clinicopathological Features in B-cell Lymphoma Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
배경: 대식세포집락자극인자(macrophage colony-stimulating factor, M-CSF)는 단구, 대식세포 및 골수내 전구세포의 생존과 증식을 조절한다. M-CSF는 여러 악성종양 환자의 혈청에서 높은 농도로 나타난다. 본 연구에서는 B세포림프종 환자군과 건강대조군의 혈청 M-CSF 농도를 측정하여 비교하고, B세포림프종 환자들의 혈청 M-CSF 농도와 임상 및 병리학적 특징의 연관성을 평가하고자하였다. 방법: B세포림프종 환자 101명의 초진 시의 혈청 검체와 건강대조군 48명의 혈청 검체를 대상으로 하였다. B세포림프종의 병기설정은 Lugano 분류를 따랐다. Quantikine ELISA Human M-CSF Immunoassay (R&D Systems, Inc., USA)를 사용하여 혈청 M-CSF 농도를 측정하였다. 건강대조군의 혈청 M-CSF의 95 백분위수에 따른 참고범위를 설정하였으며, 임상 및 병리학적 특징을 조사하였다. 결과: 건강대조군의 혈청 M-CSF의 95 백분위수에 따른 범위는 48.8-173.0 pg/mL였다. B세포림프종 환자군과 건강대조군의 혈청 M-CSF 수치 비교에서 평균±표준편차는 각각 293.3±270.9 pg/mL와 97.3±34.6 pg/mL로 나타났으며 두 군 간에 유의한 차이를 보였다(P<0.001). B세포림프종 환자 중 60세를 초과한 연령군(P =0.027), 광범위큰B세포림프종 환자군(P =0.046), 진행병기의 환자군(P<0.001), 비정상 유리경쇄비를 가진 환자군(P =0.036), 고위험군에 해당하는 국제예후지표 점수의 환자군(P<0.001), 참고범위보다 높은 젖산탈수소효소 수치의 환자군(P =0.002)에서 혈청 M-CSF가 유의하게 높게 나타났다. 결론: B세포림프종 환자에서 혈청 M-CSF 농도의 증가는 불량한 예후를 반영하는 임상 및 병리학적 지표들과 연관성을 나타내어 B세포림프종 환자의 예후를 예측할 수 있는 보조지표로서의 가능성을 보여준다.
Abstract
Background: Macrophage colony-stimulating factor (M-CSF) regulates the proliferation and supports the viability of monocytes, macrophages, and their bone marrow progenitors. M-CSF is found in high concentrations in the serum of patients with various malignancies. This study aimed to evaluate the association between serum levels of M-CSF and clinicopathological features in a B-cell lymphoma patient group. Methods: Data of 101 patients with B-cell lymphoma and 48 healthy control subjects were evaluated. Staging for B-cell lymphoma was performed according to the Lugano criteria. Serum M-CSF concentrations were measured using the Quantikine ELISA Human M-CSF Immunoassay (R&D Systems, Inc., USA). We established a 95th percentile reference interval in healthy controls and reviewed the clinicopathological characteristics. Results: The 95th percentile of the serum M-CSF in healthy controls was 48.8–173.0 pg/mL. The mean serum M-CSF level in the patient group was significantly higher than that in the healthy control group (293.3±270.9 pg/mL vs. 97.3±34.6 pg/mL, P <0.001). The mean M-CSF level was significantly higher in patients aged >60 years (P =0.027), and those with diffuse large B-cell lymphomas (P =0.046), advanced stages (P <0.001), abnormal free light chain ratios (P =0.036), high-risk international prognostic index scores (P <0.001), and lactate dehydrogenase above the reference range (P =0.002). Conclusions: Our findings suggest that elevated serum M-CSF levels have an association with adverse clinicopathological features in B-cell lymphoma patients and may be a potential prognostic predictor.
참고문헌 (17)
- Stanley ER, "Biology and action of colony–stimulating factor-1", Mol Reprod Dev, 46, pp.4~10 (1997)
- Fixe P, "Macrophage colony-stimulating-factor(M-CSF or CSF-1)and its receptor : structure-function relationships", Eur Cytokine Netw, 8, pp.125~136 (1997)
- Moore MAS, "Colony-stimulating factors: molecular and cellular biology" (1997), CRC Press
- Sherr CJ, "Peptide growth factors and their receptors I" (1991), pringer-Verlag New York
- Ide H, "Serum level of macrophage colony-stimulating factor is increased in prostate cancer patients with bone metastasis", Hum Cell, 21, pp.1~6 (2008)
- Janowska-Wieczorek A, "Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies", Blood, 77, pp.1796~1803 (1991)
- Nakayama-Ichiyama S, "Macrophage colony-stimulating factor produced by diffuse large B-cell lymphoma", Br J Haematol, 149, pp.310~ (2010)
- Nishiwaki U, "Classical Hodgkin lymphoma producing macrophage colony-stimulating factor with resultant monocytosis", Br J Haematol, 176, pp.343~ (2017)
- Suzuki M, "Serum level of macrophage colony–stimulating factor as a marker for gynecologic malignancies", Oncology, 52, pp.128~133 (1995)
- Kowalska M, "Serum macrophage colony-stimulating factor(M-CSF)in patients with Hodgkin lymphoma", Med Oncol, 29, pp.2143~2147 (2012)
- Mroczko B, "Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis", Clin Chim Acta, 380, pp.208~212 (2007)
- Suzuki M, "Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary", Gynecol Oncol, 77, pp.405~409 (2000)
- Kaminska J, "Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF-an independent prognostic factor", Oncology, 70, pp.115~125 (2006)
- Suzuki M, "Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary", Gynecol Oncol, 68, pp.35~37 (1998)
- Furtado M, "Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma", Br J Haematol, 160, pp.63~69 (2013)
- Moghimi M, "Association between abnormal serum free light chains ratio and known prognostic factors in lymphoma; a nephrology viewpoint", J Renal Inj Prev, 6, pp.148~152 (2016)
- Maurer MJ, "Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma", J Clin Oncol, 29, pp.1620~1626 (2011)